Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629775 | 1.00 | KMT2A (0.54) | KMT2AEPHX2CASP3BMP1CA1 | |
| Hydrochloric Acid SCHEMBL5629777 | 0.99 | KMT2A (0.53) | KMT2AEPHX2CASP3BMP1CA1 | |
| Hydrochloric Acid SCHEMBL5629771 | 0.99 | KMT2A (0.53) | KMT2AEPHX2CASP3BMP1CA1 | |
| SCHEMBL26857893 | 0.90 | KMT2A (0.54) | KMT2AEPHX2CASP3BMP1FABP5 | |
| SCHEMBL3871611 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3BMP1FABP5 | |
| SCHEMBL16623132 | 0.88 | KMT2A (0.55) | KMT2AEPHX2CASP3BMP1CA1 | |
| SCHEMBL31041102 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3BMP1FABP5 | |
| SCHEMBL8170342 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3BMP1FABP5 | |
| SCHEMBL25444783 | 0.88 | KMT2A (0.50) | KMT2AEPHX2CASP3BMP1 | |
| SCHEMBL17106632 | 0.88 | KMT2A (0.50) | KMT2AEPHX2CASP3BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185128-A1 | Compounds and compositions for treating obesity | NOVO NORDISK A/S (DK) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185128-A1 | Compounds and compositions for treating obesity | MC4R, MC5R, MC3R | KMT2A 2554/4885EPHX2 2194/4885CASP3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.